Followers | 130 |
Posts | 5498 |
Boards Moderated | 0 |
Alias Born | 06/09/2020 |
Monday, September 19, 2022 1:54:37 AM
Few have realized what kind of stamina has brought NWBO, where they are today.
Few knows of the history of the last 25 year, where Jeannine Walston today is living on her 24th year.because of Linda Liau.
This board would've been closed some years ago, hadn't it been for collective foresight of the NWBO management.
If anyone has studied Linda Powers, she has not taken this road to be here today, just to sell for measly $7 or there about.
NWBO has been built up brick by brick for either a future maximum exit sale, or doing it themselves until they get the maximum exit sale.
We don't know the obstacles that have been thrown at them during the years, outside of the harassment from dudes like Adam Feuerstein and the hordes of pawns doing the market makers bidding on stock boards and social medias.
Information entropy tells us, that the extreme kind of involvement from top to bottom of the bearish hierarchy, is a clear sign of the disruption NWBO and DCvax-L brings to "the game".
it is a game changer that big pharma et al had not counted on would be in a position today, where production and infrastructure was build and ready to start commercialization. Where +60 people doing NWBOs bidding were ready with state of the art equipment and specialized hired people. Where they sat on 270 global patents and very soon a combo patent making it possible for them to combine DCvax-L with every kind of checkpoint inhibitors.
People might not like the waiting time to get here, but it was either that or getting the kiss of death.
How do one get the first immunology cancer treatment approved? The obstacles were many. Hammering the head into PFS endpoint because immunology progression tells a different tale than we are used to. So we switch endpoints to OS. We measure ourselves with external control arms. We rather add more years to the waiting time by not only grow the tale of long time survivors, but also buy and develop and refine a technology, that makes it possible for NWBO to automate and scale the personal doses of DCvax-L.
EVERYTHING is done with UTMOST care and study of WHAT could make the trial fail. In order not to be one of the 397 other trials that have failed before DCVax-L.
Beyond the extraordinary achievement of science that Linda Liau has made, it is such an incredible feat that LP and co have done to have brought NWBO to the starting line with almost everything ready to go.
Not only that. DCVax-L has been qualified by UCLA and Merck by being the secret sauce of the UCLAs most prestigious of cancer research projects.
The SPORE 1 project. And everything back to the DCvax-L and Nivolumab trial with Bristol Meyers Squibb and Duffy entering the stage, and the trial is exchanged to a Keytruda trial, stinks of Merck involvement.
It is a definite, that NWBO is not about to be sold for petty cash. Everything can be read out of the transcripts of the annual shareholders meeting. The kind of stamina that Linda Powers and co. has expressed and what they went through and what they have build up like NONE before them, is not going to be auctioned away cheap.
She's not adding a competent US/Global PR man "to the mix" at this time, because a cheap deal is made in the dark. She is going to want to PR the success and let it hit news media, just like the 2018 interim data hit Guardian, Daily Mail, BBC and more and tirelessly work the SP up along with the catalysts that has been accumulated during the quiet period.
I don't get the pessimism at all some retailers have, with what we can see with our own eyes happening.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2024 09:24:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:01:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:06:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 02:42:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
FEATURED North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • Nov 4, 2024 9:00 AM
Rainmaker Worldwide Inc. Announces Strategic Partnership Between Miranda Water Technologies and Fleming College • RAKR • Nov 4, 2024 12:03 PM
Rainmaker Worldwide Inc. to Assume Direct, Non-Dealer Sales of Miranda Water Technologies in U.S. and Mexico in First Quarter of 2025 • RAKR • Nov 4, 2024 8:31 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM